Research Article
Investigating the Presence of Falsified and Poor-Quality Fixed-Dose Combination Artemether-Lumefantrine Pharmaceutical Dosage Forms in Kumasi, Ghana
Table 3
Results of analyses of market samples using the developed RP-HPLC method.
| Formulation | Sample code | Retention time L/A (min) | Percentage content of artemether (%) SD | ΨPercentage content of lumefantrine (%) | Remarks on API content |
| Tablet | LZT | 1.44/5.38 | 97.76 1.03 | 91.81 1.14 | Passed | LNT | 1.41/5.38 | 99.68 0.89 | 97.55 ± 1.05 | Passed | MLT | 1.39/5.36 | 99.50 0.23 | 98.33 1.23 | Passed | LFT | 1.40/5.38 | 99.49 0.18 | 96.83 0.28 | Passed | CTT | 1.41/5.37 | 99.89 0.76 | 99.12 0.97 | Passed | TMT | 1.39/5.38 | 96.90 0.25 | 91.64 1.11 | Passed | IDT | 1.40/5.38 | 94.94 0.06 | 92.16 1.26 | Passed | DMT | 1.39/5.38 | 99.68 0.34 | 96.52 0.73 | Passed |
| Suspension | MLS | 1.42/5.30 | 98.37 0.54 | 99.71 0.27 | Passed | LFS | 1.42/5.40 | 99.92 0.32 | 97.98 1.09 | Passed | IDS | 1.42/5.40 | 100.10 0.25 | 91.27 1.16 | Passed | LNS | 1.42/5.43 | 98.50 0.88 | 97.72 1.02 | Passed | STS | 1.42/5.42 | 116.76 0.94 | 80.35 1.01 | Failed | BMS | 1.42/5.43 | 88.31 0.44 | 82.08 0.98 | Failed |
|
|
L = lumefantrine. A = artemether. Acceptance criteria (BP): 90%–110%. ΨAcceptance criteria (BP): 90%–110%. |